Phase I-II multicenter, randomized, open-label, clinical and pharmacokinetic study of plitidepsin, administered alone or in combination with dacarbazine, as front-line therapy to subjects with unresectable advanced melanoma

Trial Profile

Phase I-II multicenter, randomized, open-label, clinical and pharmacokinetic study of plitidepsin, administered alone or in combination with dacarbazine, as front-line therapy to subjects with unresectable advanced melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2011

At a glance

  • Drugs Dacarbazine; Plitidepsin
  • Indications Malignant melanoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors PharmaMar
  • Most Recent Events

    • 09 Jun 2010 Data will be presented at the annual meeting of the the American Society of Clinical Oncology (ASCO 2010), according to a PharmaMar media release.
    • 09 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top